Patients and Methods
From January 2008 to December 2011, 46 ATDinduced agranulocytosis patients took the treatment at the first affiliated hospital of the University of South China. Thirty three of them received a bone marrow aspirate during agranulocytosis. The medical records were reviewed for clinical features, associated drugs, bone marrow profiles and outcomes with the patients' consent. This study was approved by the institutional review board of the hospital.
The diagnosis of hyperthyroidism was made on the basis of established criteria such as high metabolic syndromes, increased radioiodine uptake, positive serum TSH receptor antibodies (TRAb), suppressed serum thyrotropin level, elevated serum free triiodothyro-cases were from type I. The mean dosage of MMI at onset of agranulocytosis was 19.1 ± 5.5 mg/day (n =16, 10～30 mg/day) in type I and 17.9 ± 6.4 mg/day (n =7, 10～30 mg/day) in type II, while the dosage of PTU at the time the patients developed agranulocytosis was 187.5 ± 47.9 mg/day (n =4, 150～250 mg/day) in type I and 166.7 ± 40.8 mg/day (n =6, 100～300 mg/day) in type II .
Comparison of bone marrow features between two types
According to the degree of bone marrow prolifera-nine and thyroxine. Ultrasonograph was performed to find out the lesions of the thyroid. Agranulocytosis was defined as a circulating absolute neutrophil count (ANC) lower than 500/µL. Causes of other drugs or blood diseases were excluded. Blood absolute neutrophil count was greater than 1.5×10 9 /L before receiving ATD treatment. On admission, all patients were recommended to suspend ATD immediately and were admitted to a single ward with barrier nursing and isolation precaution. Intravenous antibiotics were prescribed to control infection and G-CSF was applied to raise neutrophils. Statistical analysis was performed by using SPSS statistical software (Version 13.0). Values were expressed as mean ± standard deviation. Independent sample test was used for comparison between the two types. p value of 0.01 or less was considered significant.
results

Classification of bone marrow characteristics
There were 46 ATD-induced agranulocytosis in-patients in our hospital from January 2008 to December 2011. Thirty three of them received the bone marrow examination during agranulocytosis. The bone marrow features of them basically fell into two types: type I was characterized by selective reduction or absence of granulocytic precursors with normal or increased erythropoiesis and megakaryocyte proliferation ( Fig. 1a ) and type II was recognized as left-shifted granulopoiesis with few or no mature granulocytes beyond myelocytes ( Fig. 1b ).
General condition
As is shown in Table 1 , of all 33 patients, there were 8 males and 25 females. Twenty-three (70%) cases were derived from MMI and ten (30%) from PTU. There were 20 cases (61%) whose bone marrow characterized with type I and 13 cases (39%) with type II. Two death Agranulocytosis is the most serious side effect of ATD therapy. The mortality secondary to ATD-induced agranulocytosis has been reported as high as 21.5% [10] . Pathogenic mechanisms of these adverse reactions are not completely understood. There are two major hypotheses, including direct toxic effects and immunological reactions [1] . ATD can easily penetrate into the bone marrow affecting oxygen and glucose utilization of leukocytes through the oxidized metabolites [11] . Therefore, it may affect the microenvironment of bone marrow and inhibit the generation and differentiation of pluripotent hematopoietic stem cells. The immunological reactions include the immunoglobulin (Ig) E-mediated hypersensitivity reaction, drug-induced IgG and IgM responses, and antineutrophil cytoplasm antibodies (ANCA) associated immune injury, which might contribute to agranulocytosis [1, 7, [12] [13] . Bone marrow characteristics may be valuable in revealing the tion of the 33 cases, there were 15 cases with bone marrow active proliferation, 3 cases with hyperplasia and 2 cases with hypoplasia in type I, while 3 cases with hyperplasia and 10 cases with active proliferation were indentified in type II. A comparison between the two patterns of bone marrow characteristics was listed in Table 2 , the ratio of granulocytes in each stage of type I were significantly lower than that of type II, but there was no difference in proportion of erythrocyte in each stage between the two groups.
Clinical characteristics
Comparison between the two patterns of clinical characteristics was shown in Table 3 . There was no obvious difference in age, duration of drug exposure, absolute neutrophil count on admission and the total administration dose of G-CSF before bone marrow aspirate between the two groups, but the median duration of fever and neutrophil recovery in type I were obviously longer than those of type II. ANC, absolute neutrophil count; G-CSF, granulocyte-colony stimulating factor; -X±s, mean ± standard deviation patients developed sudden onset agranulocytosis and hepatotoxicity after taking methimazole within 6 days. This is the first case of agranulocytosis and hepatotoxicity induced by methimazole in less than 6 days [20] . The data from our study also revealed that the onset age, period of drug exposure, associated drugs (MMI or PTU) and neutrophil count on admission have no significant effect on the types of bone marrow. But the duration of granulocyte recovery and fever of type I patients was significantly longer than that of type II. All patients in type I showed symptoms of infections such as fever, sore throat and cough, two of them died of complications from infection, while two cases in type II were asymptomatic when agranulocytosis was detected. They were treated appropriately and had no symptom of infection throughout the course of the disease, despite the absence of granulocytes in circulation. These data indicated that cases of type I were more susceptible to infection, and it was difficult to be effectively controlled once infected. Therefore, a bone marrow aspirate may be useful in predicting the prognosis of ATD-induced agranulocytosis. G-CSF was found to be useful in shortening the duration of granulocyte recovery in ATD-induced agranulocytosis [21] . Although there were some studies showed disparate opinions on its effect [8, [22] [23] , most authorities recommended using G-CSF for agranulocytosis due to ATD [1, 4, 21] . The action of G-CSF included stimulation and differentiation of myeloid granulocyte progenitors, squeezing mature granulocytes from bone marrow and shifting neutrophils from the perivascular space to the vascular space [24] . All 33 patients in our study received G-CSF treatment to improve granulocytes. We found that there was no obvious difference in the total administration dose of G-CSF before bone marrow aspirate between the two types, while the duration of neutrophil recovery in type II was obviously shorter than that of type I. These results may indicate that G-CSF was more useful in patients with type II bone marrow characteristics.
However, as a retrospective analysis, we have not observed the dynamic changes of bone marrow characteristics in the process of recovery. All of the 33 cases received bone marrow aspirate during agranulocytosis, but none of them have been re-examined after recovery. In addition, due to the relatively small group of patients, the relationship between bone marrow features and clinical outcomes need to be further assessed in future prospective clinical studies with more patients. Our etiology of the diseaese [10, 14] . Direct toxic effects are often non-selective to hematopoietic stem cells. Therefore, hypoplasia with decreased or absent of precursor cells is the common characteristics of drug toxicity [10] . However, ATD related immune complexes may selectively react on antigen targets on the surface of mature granulocytes or granulocyte progenitor cells [6, 12] . The hematopoietic function of bone marrow is not completely inhibited. So it is usually featured with active proliferation or hyperplasia and decreasing of mature granulocytes and granulocyte progenitor cells. Our study has provided a preliminary bone marrow data of ATD-induced agranulocytosis which can be divided into two categories as described above. Both types of the bone marrow show that only the granulocytes have reduced while the erythrocytes and platelets remain normal. The results indicate that the pathogenesis may be antibodies directed against mature granulocytes or granulocyte progenitor cells rather than drug toxicity directly. The classification of the myeloid features may be related to the severity of the immune response.
Aplastic anemia also occurs in some patients administered ATD. Its incidence, however, was much lower than that of agranulocytosis. To date, there were only 42 cases of ATD-induced aplastic anemia reported [15] [16] . It has been suggested that the most likely mechanism for ATD-induced aplastic anemia was also an autoimmune humoral reaction against myeloid stem cells rather than granulocyte progenitor cells and mature circulating neutrophils [2, [17] [18] . As all patients with ATD-induced aplastic anemia had concomitant agranulocytosis, it was probable that these two side effects had some overlap in pathogenesis. Comparative analysis of the bone marrow characteristics of the two conditions may provide clues to reveal the pathogenesis. However, as for the limited number of cases in this study, we didn't get the sample of aplastic anemia and the bone marrow characteristic of aplastic anemia was not mentioned in the forward tables.
It has been reported that ATD-induced agranulocytosis usually develops within 3 to 4 months after administration and patients over 40 years old may be more vulnerable to this condition [1, 19] . Our study has got the similar results. Most of the 33 patients developed agranulocytosis within 10 weeks (7.3 ± 3.9 weeks in type I, 8.2 ± 3.6 weeks in type II) and the average age was 37.4 years (36.4 ± 10.9 years in type I, 39.0 ± 13.8 years in type II). Interestingly, one of our
